Pharmacological approach for drug repositioning against cardiorenal diseases

Yoshito Zamami, Masaki Imanishi, Kenshi Takechi, Keisuke Ishizawa

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)


New applications of approved clinically used drugs are being discovered. Drug repositioning is a proposed strategy for developing these drugs as therapeutic agents for different diseases. Currently, approximately 2000 drugs are used in Japan. However, the compound targets and pathways involved in the pharmacological actions of 70-80% of these drugs have not been adequately clarified. Pharmacological examination of approved drugs is an important task in drug repositioning and vital for improving drug development efficiency. This review reports that angiotensin II type 1 receptor blockers show receptor-independent effects against reactive oxygen species generation in renal cells. Additionally, nitrosonifedipine has an antioxidative effect and protects endothelial cells against oxidative stress, and pioglitazone has multiple effects that improve dysfunctions in vascular control regulated by adrenergic and calcitonin gene-related peptide-containing nerves in animal models of diabetes. These data suggest that some approved drugs could be useful for treating cardiorenal diseases. Since cardiorenal diseases are likely to have chronic pathological conditions and require chronic drug administration, highly safe drugs are needed. Compared to newly developed drugs, drug repositioning of approved drugs with safety information is considered a particularly useful technique for searching new treatments for cardiorenal diseases.

Original languageEnglish
Pages (from-to)197-201
Number of pages5
JournalJournal of Medical Investigation
Issue number3-4
Publication statusPublished - 2017
Externally publishedYes


  • Cardiorenal diseases
  • Drug repositioning
  • Pharmacology

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Pharmacological approach for drug repositioning against cardiorenal diseases'. Together they form a unique fingerprint.

Cite this